Dependence on overseas production bases in Thailand, Vietnam and the Philippines
First written in FY2016. 3 of 9 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2022: 27 of 57 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The Group is continuously transferring production from its largest production base, ASAHI INTECC THAILAND CO.,LTD., to its second production base, ASAHI INTECC HANOI CO.,LTD. It is also developing a production system at its third production base, TOYOFLEX CEBU CORPORATION, capable of manufacturing medical devices, thereby diversifying its risks.」
The Group continues its policy of diversifying production across 3 facilities in Thailand, Hanoi and Cebu and reducing risk. - FY2022-Q3MaterialisedAnnual report
「On 16 December 2021, Typhoon Rai (Typhoon No. 22) struck the Philippines, causing damage mainly to the device business of our consolidated subsidiary TOYOFLEX CEBU CORPORATION (the Cebu factory), but operations have been gradually resuming since mid-January. During the nine-month period under review, we recorded part of the losses from the typhoon damage as an extraordinary loss. However, part of the damage is covered by insurance proceeds, and there has been no material impact on the group’s results for the current fiscal year as a whole.」
The damage to and suspension of operations at the Cebu plant, one of the overseas production facilities on which the Group depends, were disclosed as having a continuing impact, and an extraordinary loss of ¥477 million was recorded. Operations resumed sequentially from mid-January. - FY2022-Q2MaterialisedAnnual report
「On 16 December 2021, Typhoon Rai, known as Typhoon No. 22, struck the Philippines, damaging the consolidated subsidiary TOYOFLEX CEBU CORPORATION (the Cebu plant), particularly its device business.」
The Cebu plant, one of the overseas production facilities on which the Group depends, was damaged by a typhoon, resulting in an actual suspension of operations. - FY2021RestatedAnnual report
「The Group is continuously transferring production from its largest production base, ASAHI INTECC THAILAND CO.,LTD., to its second production base, ASAHI INTECC HANOI CO.,LTD. It is also developing a production system at its third production base, TOYOFLEX CEBU CORPORATION, capable of manufacturing medical devices, thereby diversifying its risks.」
The Group continues its policy of reducing dependence risk by diversifying production across 3 facilities in Thailand, Hanoi and Cebu and supporting medical device production. - FY2020-Q3MaterialisedAnnual report
「Following the issuance of a stay-at-home order in Cebu Province, Philippines, the consolidated subsidiary TOYOFLEX CEBU CORPORATION (the Cebu plant) is temporarily operating on a limited basis. Alternative production necessitated by the reduced operating rate at the Cebu plant is being carried out at the Group's main plants, ASAHI INTECC THAILAND CO.,LTD. (the Thailand plant) and ASAHI INTECC HANOI CO.,LTD. (the Hanoi plant).」
Reduced operations at the Cebu plant, one of the overseas production facilities, actually occurred, and the Thailand and Hanoi plants are providing alternative production. - FY2019RestatedAnnual report
「The Group is continuously transferring production from its largest production base, ASAHI INTECC THAILAND CO.,LTD., to its second production base, ASAHI INTECC HANOI CO.,LTD. It is also developing a production system at its third production base, TOYOFLEX CEBU CORPORATION, capable of manufacturing medical devices, thereby diversifying its risks.」
The Group continues to diversify the risk of concentration in overseas production by transferring production from Thailand to Hanoi and establishing a system for medical device production in Cebu. - FY2018MitigatedAnnual report
「The Group is continuously transferring production from its largest production base, ASAHI INTECC THAILAND CO.,LTD., to its second production base, ASAHI INTECC HANOI CO.,LTD. It is also developing a production system at its third production base, TOYOFLEX CEBU CORPORATION, capable of manufacturing medical devices, thereby diversifying its risks.」
The Group continues to diversify the risk of concentration in overseas production by transferring production from Thailand to Hanoi and establishing a system for medical device production in Cebu. - FY2017MitigatedAnnual report
「The Group is continuously transferring production from its largest production base, ASAHI INTECC THAILAND CO.,LTD., to its second production base, ASAHI INTECC HANOI CO.,LTD. It is also developing a production system at its third production base, TOYOFLEX CEBU CORPORATION, capable of manufacturing medical devices, thereby diversifying its risks.」
The Group is diversifying the risk of concentration at overseas production facilities through the ongoing transfer of production from Thailand to Hanoi and by establishing the Cebu plant to support medical device production. - FY2016First statedAnnual report
「The Group positions its facilities in Japan primarily as research and development bases, while positioning its consolidated subsidiaries ASAHI INTECC THAILAND CO.,LTD., ASAHI INTECC HANOI CO.,LTD. and TOYOFLEX CEBU CORPORATION as important production bases. Mass-produced products are currently, in principle, being transferred to these consolidated subsidiaries for production.」
Mass-production functions have been transferred to 3 production facilities in Thailand, Vietnam and the Philippines. Risks include reduced or suspended operations resulting from natural disasters, political and economic conditions, labor shortages and other factors.